Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk Ventilation 25% c19early.org/o Salah et al. Colchicine for COVID-19 META ANALYSIS Favors colchicine Favors control
Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19
Salah et al., The American Journal of Cardiology, doi:10.1016/j.amjcard.2021.02.005
Salah et al., Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19, The American Journal of Cardiology, doi:10.1016/j.amjcard.2021.02.005
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Meta analysis of 8 studies, showing significantly lower COVID-19 mortality with colchicine.
Currently there are 48 colchicine studies and meta analysis shows:
OutcomeImprovement
Mortality33% lower [21‑43%]
Ventilation29% lower [-15‑56%]
ICU admission25% lower [3‑43%]
Hospitalization17% lower [8‑25%]
Cases9% more [-6‑27%]
risk of death, 38.0% lower, RR 0.62, p < 0.001.
risk of mechanical ventilation, 25.0% lower, RR 0.75, p = 0.27.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Salah et al., 30 Apr 2021, peer-reviewed, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: 170 The American Journal of Cardiology (www.ajconline.org) time frame analysis showed a significant drop in hospitalization rates just after PC encounters, and continued to decrease over time (Panel A). The annual trends for 90-day all-cause hospitalization rates before PC encounters showed a significant reduction over time (59.7% in 2010 to 53.3% in 2018, p <0.001), but hospitalization rates after PC remained stable over the study period (Panel B). In this observational nationwide analysis of over 25,000 acute on chronic HF admissions, PC encounters were associated with a significant reduction in all-cause, HF-specific, and non-HF 90-day hospitalization rates. This reduction was noted immediately after discharge from the index admission with a PC encounter. Hospitalization rates before PC utilization decreased over the study period perhaps due to the early recognition of value of PC among these sick patients. This study is limited by the nature of this administrative database which carries a risk of mis- or under-coding. Additionally, we could not identify patients who died after hospital discharge. Some of the reduction in readmission may be due to this factor. However, it is unlikely that death would account for the entire decrease in admission rates after a hospital PC consultation, since not all patients seen by PC physicians are appropriate for hospice or accept a palliative approach to care, and the previously reported post-HF discharge 30-day mortality rate »7% (1). Moreover, the philosophical change of care to a palliative approach encourages a decrease in low-value health care utilization such as repeat hospital admissions at the end of life. In summary, we found that patients who received a PC encounter during a hospitalization had a reduction in subsequent readmission rates. Further studies should assess the competing risk of death in this population. Disclosure: The authors have nothing to disclose, and no relationship with industry. Funding: Self-funded Ahmed Elkaryoni, MDa,* Brett W. Sperry, MDb Anna Royce, MDc Kevin Walsh, MDd Elizabeth Bruno, MDd Subir Shah, DOa,d Amir Darki, MD MSca,d Islam Y. Elgendy, MDe a Division of Cardiovascular Disease, Loyola University Medical Center, Loyola Stritch School of Medicine, Maywood, Illinois b Division of Cardiovascular Disease, Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri c Department of Internal Medicine, University of Oklahoma, Oklahoma d Department of Internal Medicine, Loyola University Medical Center, Loyola Stritch School of Medicine, Maywood, Illinois e Divison of Cardiology, Weill Cornell MedicineQatar, Doha, Qatar 27 January 2021 1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics2020 update: a report from the American Heart Association. Circulation 2020;141:e139–e596. 2. Diop MS, Bowen GS, Jiang L, Wu WC, Cornell PY, Gozalo P, Rudolph JL...
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit